This application is related to co-pending U.S. patent application Ser. No. 11/066,346 entitled “Minimally-Invasive Cardiac-Valve Prosthesis,” and claims priority from Italian patent application number TO2005/A000074, filed on Feb. 10, 2005. Each of the above-identified applications is hereby incorporated by reference for all purposes.
The present invention relates to cardiac-valve prostheses. More specifically, the present invention is directed to a prosthesis that is amenable to a minimally-invasive implantation.
Recently, there has been increasing consideration given to the possibility of using, as an alternative to traditional cardiac-valve prostheses, valves designed to be implanted using minimally-invasive surgical techniques or endovascular delivery (the so-called “percutaneous valves”). Implantation of a percutaneous valve (or implantation using thoracic-microsurgery techniques) is a far less invasive act than the surgical operation required for implanting traditional cardiac-valve prostheses. Further details of exemplary percutaneous implantation techniques are provided in U.S. Publication 2002/0042651, U.S. Pat. No. 3,671,979, and U.S. Pat. No. 5,954,766, which are hereby incorporated by reference.
These prosthetic valves typically include an anchoring structure, which is able to support and fix the valve prosthesis in the implantation position, and prosthetic valve elements, generally in the form of leaflets or flaps, which are stably connected to the anchoring structure and are able to regulate blood flow.
Furthermore, the methods of implantation of valves via a percutaneous route or by means of thoracic microsurgery are very frequently irrespective of the effective removal of the natural valve leaflets. Instead, the cardiac valve may be introduced in a position corresponding to the natural annulus and deployed in situ by simply divaricating definitively the natural valve leaflets.
There is a need for a percutaneous valve that does not run the risk of being displaced (dislodged) with respect to the implantation position, as a result of the hydraulic thrust exerted by the blood flow. There is a further need for a percutaneous valve that secures tightly to the flow duct generally defined by the natural valve annulus, such that it resists blood flow around the outside of the percutaneous valve structure.
In an exemplary embodiment, a cardiac valve prosthesis according to the invention is made so that the entire armature of the valve, or at least the anchorage parts, adhere to the native walls of the implantation site, without interfering with the blood flow, which thus remains practically free. In a preferred way, the anchorage portions moreover have appropriate slits that prevent their interference with the coronary ostia. The anchorage portions and the portions of functional support of the armature can constitute either different parts of a single structure or parts that are structurally distinct from one another. Super-elastic materials can be used in order to obtain a structure that is able to be collapsed for advancement to its implantation site, and to self-recover its expanded geometry once the prosthesis is deployed in the implantation position. The entire armature of the valve, or at least the anchorage parts, can be made even of re-absorbable material, whereas the valve leaflets can be made of biological and/or synthetic tissues, in part colonizable or re-absorbable. In this way, it is possible to obtain anchorage of the device during the period necessary for integration of the valve prosthesis with the physiological tissues of the anatomical site of implantation. Subsequently, there is dissolution of the artificial structure that enables initial anchorage. Amongst the various advantages linked to this solution to be emphasized is the creation of the ideal conditions for a possible prosthetic re-implantation. The armature can include anchorage formations or portions of the supporting structure of the valve flaps made at least partially of shape-memory material (e.g., Nitinol) that enable creation or regulation of the anchorage, i.e., regulation of the modalities and the magnitude of splaying-out of the valve leaflets through control of the memory of the shape-memory material (e.g., by controlling its temperature), according to a mechanism similar to what is described in the document No. EP-A-1 088 529.
While multiple embodiments are disclosed, still other embodiments of the present invention will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. As will be realized, the invention is capable of modifications in various obvious aspects, all without departing from the spirit and scope of the present invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.
The invention will now be described, purely by way of non-limiting example, with reference to the annexed plate of drawings, in which:
While the invention is amenable to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and are described in detail below. The intention, however, is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims.
In the figures of the annexed plate of drawings, the reference number 1 designates as a whole a cardiac-valve prosthesis, which can be implanted percutaneously or resorting to techniques of thoracic microsurgery, or else of implantation of a “sutureless” type. Essentially, the prosthesis 1 represented in
As illustrated in
The valve sleeve 3 may be constructed according to various techniques known in the art. For example, techniques for the formation of the valve leaflets, assembly of the valve sleeve and installation thereof on an armature that can be used in the context of the present invention are described in EP-A-0 133 420, EP-A-0 155 245 and EP-A-0 515 324 (all of which are hereby incorporated by reference), the latter document referring to the construction of a cardiac-valve prosthesis of biological tissue of the type commonly referred to as “stentless.”
As further illustrated, the valve sleeve 3 includes a base portion 30 with an overall annular pattern, designed to extend from the lower portion of the prosthesis 1, which, in the implantation site, is in a position proximal with respect to the direction of flow of the blood through the prosthesis (from below upwards, as viewed in
As illustrated in
As will be understood by those of ordinary skill in the art, in operation, the valve leaflets 3a, 3b, 3c are able to undergo deformation, divaricating and moving up against the armature 2 so as to enable free flow of the blood through the prosthesis. When the pressure gradient, and hence the direction of flow, of the blood through the prosthesis tends to be reversed, the valve leaflets 3a, 3b, 3c then move into the position represented in
During implantation, the prosthesis 1 is advanced towards the implantation site in a radially contracted configuration, with the annular elements 20a and 20b in a radially collapsed configuration. In one embodiment, when so collapsed, the annular elements 20a, 20b have a minimum diameter of about 5 to about 15 mm, according to the technique of implantation for which the prosthesis is designed. Once the prosthesis 1 has reached the implantation site, the annular elements 20a, 20b are made/allowed to expand until they reach their normal expanded configuration, with a diameter that ranges, in one embodiment, from about 18 to about 30 mm.
In order to enable the movement of expansion, the annular elements 20a and 20b are made, according to the illustrated embodiment, with a mesh structure substantially resembling the mesh structure of a stent for angioplasty. It will be appreciated in fact that the annular elements 20a and 20b are designed to perform a movement of radial expansion (with subsequent maintenance of the radially expanded configuration) substantially resembling the movement of expansion in situ of an angioplasty stent.
In the example of embodiment illustrated herein, the annular elements 20a and 20b have a rhomboidal-mesh structure. In other embodiments, the parts 20a, 20b can be made with any structure that is able to ensure the necessary functionality.
In one embodiment, as shown in
As shown, the annular elements 20a, 20b are connected to one another by anchor members 22, which in the illustrated embodiment, are generally arched, projecting towards the outside of the prosthesis 1. In one embodiment, the anchor members 22 are designed such that when the prosthesis 1 is positioned at the implantation site, the anchor members 22 can extend on the outside of the sinuses of Valsalva so as to ensure firm anchorage in situ of the prosthesis 1.
With the prosthesis 1 in the radially contracted configuration adopted for implantation, the anchor members 22 are normally maintained in a position (not shown) recalled towards the central axis X1 of the prosthesis 1. This can occur, for example, via a retention means such as a tubular sheath of an implantation catheter through which the radially contracted prosthesis is advanced. Subsequently, once disengaged from the retention means, the anchor members 22 may assume the arched pattern represented in the figures so as to be able to project (protrude), in one embodiment, within the sinuses of Valsalva.
As will be appreciated by those skilled in the art, the sinuses of Valsalva are, in a normal heart, three in number, and are distributed in an approximately angularly uniform way around the root of the artery distal to the semilunar valve (i.e., the aortic or pulmonary valve). Accordingly, as illustrated, the prosthesis 1 may include three anchor members 22 (or three groups of anchor members) set at an angular distance apart of about 120° with respect to the central axis X1 of the prosthesis.
In the exemplary embodiment illustrated, the anchor members 22 are made in the form of ribbon-like elements that extend in a generally sinusoidal or serpentine path, with bends or open loops situated on either side with respect to an ideal line extending approximately in the direction of the generatrices of the overall cylindrical shape of the prosthesis. In another embodiment of the invention, the sinusoidal pattern can be obtained with bends or open loops that extend from one side and from the other with respect to a line that extends in a circumferential direction with respect to the prosthesis. In yet another embodiment, the anchor members 22 may have a mesh structure, for example closed rhomboidal meshes of the same type as the one represented with reference to the annular elements 20a, 20b, or to simple segments of curve lying in roughly radial planes. Additionally, as discussed above, each anchor member 22 can consist either of a single element or of a plurality of elements (e.g., pairs of anchor members 22 as shown in
The annular elements 20a and 20b and the respective anchor members 22 substantially form the basic structure of the armature 2 of the prosthesis 1, which is designed to ensure positioning and anchorage in situ of the prosthesis 1 itself.
Associated then to the annular elements 20a and 20b are further support members, generically designated by 24 in all of
As may be appreciated from a comparative examination of
In this regard, both the armature 2 and the aforesaid suturing stitches can be advantageously provided with a coating of biocompatible carbon material, which may be applied according to the solutions described in U.S. Pat. Nos. 4,624,822, 4,758,151, 5,084,151, 5,133,845, 5,370,684, 5,387,247, and 5,423,886, the contents of which are hereby incorporated by reference.
The apertured structure of the supporting formations 24, and of the armature 2 in general, means that the armature 2 does not exert any substantial obtrusive effect, preventing, for example, interference in regard to the coronary ostia.
As further shown in
The solution represented in
In the embodiment represented in
Yet another embodiment is shown in
As shown, the overall configuration of the embodiment of
In another embodiment (not shown), the supporting elements 36 may be configured to extend from the support members 24 extending in cantilever fashion from the annular element 20a.
As will be readily understood by those skilled in the art, festoon-like or catenary pattern of the supporting elements 36 may be generally configured to match the homologous pattern of the proximal edges of the valve leaflets 3a, 3b and 3c (see
The embodiments of the present invention described herein enables, in the final position of implantation, the entire armature 2 of the prosthesis 1, or at least the anchorage parts, to adhere to the native walls of the implantation site, without interfering with the blood flow, which thus remains practically free. Additionally, the armature 2 and anchor members 22 moreover have a generally apertured structure (for example, appropriate slits), which prevents interference with the coronary ostia.
The anchorage portions and the portions of functional support of the armature 2 can constitute either different parts of a single structure or parts that are structurally distinct from one another. The entire armature 2, or at least the anchorage parts (e.g., the anchor members 22), may be made of re-absorbable material, whereas the valve sleeve 3 can be constituted by biological and/or synthetic tissues, which are in part colonizable or re-absorbable.
Alternatively, as discussed above, the armature 2 can contain anchorage formations (e.g., anchor members 22) made at least partially of shape-memory material (e.g., Nitinol), which enable creation or regulation of the anchorage through the control of the memory of the shape-memory material (e.g., controlling its temperature).
The armature 2 of the prosthesis 1, according to one embodiment, is manufactured by first cutting a blank part from a tube of a biocompatible metal (e.g., Nitinol, or a cobaltum-chromium alloy) having an outer diameter which is at an intermediate size between the fully radially contracted and the fully expanded device dimensions. For example, the tube may have an outer diameter of between about 8 mm to about 14 mm. In one embodiment, the tube has a diameter of about 10 mm. In one embodiment, the tube wall may vary between about 0.3 mm to about 0.5 mm, depending on the required stiffness required and the size of the prosthesis 1.
In one embodiment, the final dimension and shape of the framework is achieved by a sequence of expansion cycles. A specific heat treatment is applied after each expansion cycle to homogenize and stress relieve the material, which allows the shape and properties of the structure of the armature 2 to be set. Although the number of forming steps may vary among devices, for the geometries described above with respect to the present invention, and using Nitinol for the tube blank, an exemplary number of forming steps is around three. Among these steps, the first two provide the final diameter of the annular elements 20a, 20b. For example, if the fully-expanded diameter for implantation is 23 mm, the final cylindrical shape of the armature 2 can be achieved using a tube blank of about 10 mm in diameter, a first expansion from about 10 mm to about 18 mm, and a second expansion from about 18 mm to about 23 mm. Optionally, the final diameter can be made slightly larger (e.g. about 25 mm in the previous example) in order to oversize the armature 2 with respect to the physiological annulus, thus imparting a radial force to the wall of the annulus at the nominal implant diameter.
The third forming step is aimed to impart the radially extending shape of the anchor members 22 such that they will fit and anchor within the Valsalva sinuses. The corresponding heat treatment, according to one embodiment, includes exposing the deformed armature 2 to a temperature from about 480° C. to about 550° C., for a time ranging from about 5 minutes to about 30 minutes, depending on the desired final transformation temperature. For example, in order to obtain a super-elastic behavior at 37° C. (the normal working condition in human body) the heat treatments subsequent to the two initial expansion steps may be performed at about 480° C. for a time of about 9 minutes, and the final heat treatment (after the third expansion) is performed at about 500° C. for a time of about 9 minutes.
After the forming process is complete, the armature 2 may undergo one or more surface treatments, for example, sandblasting and electropolishing, to provide a sufficiently smooth surface and to remove the shallow defects. The armature 2 may thereafter be finally exposed to a carbon coating process in order to improve its hemocompatibility.
As shown in
According to one exemplary embodiment, H is about 0.9, Dmax is about 1.5, Hmax is about 0.35, and Dstj is about 1.2.
The commissural points of the elastic collapsible valve 3 are mounted to the armature 2 (e.g., by attachment to the support members 24) such that the valve leaflets 3a, 3b, and 3c can fold and expand together. The valve 3, including the valve leaflets 3a, 3b, 3c, can be, for example, a glutaraldehyde fixed pericardium valve which has three cusps that open distally to permit unidirectional blood flow.
In one embodiment, the valve member may use two pericardium sheets. The first sheet forms the three moving cusps, the second sheet coats part of the armature 2 surface so that there is no contact between the armature 2 and the valve leaflets avoiding the risk of abrasion due to repeated impact against the metallic material of the armature 2. In addition, this second sheet redistributes the stress applied by blood pressure on the prosthetic leaflets, avoiding the risk of stress concentration.
The two sheets of pericardium may be stitched together flat using suture thread coated with a film of biocompatible material, and then close in a cylindrical shape. The type of stitch used may be varied to accommodate the directional differences in the forces exerted at each point of the suture, to ensure that the stitches themselves don't become the origin of fatigue fracture lines. The two sheets may be stitched together in a flat position so when the leaflets open they recover their original cylindrical configuration, forming a cylindrical duct.
The elastically collapsible valve sleeve 3 can be mounted on the armature 2 by means of a number of suture stitches. Both of the sheets are useful for attaching the valve sleeve 3 to the armature 2 by stitching.
The valve member can use a tissue fixation and shaping of the leaflets 3a, 3b, 3c by means of a fluidic, atraumatic system with chemicals useful for cross-linking and then may be exposed to a detoxification post treatment to increase long-term performance. An additional pericardium sheet corresponding to base portion 30 of the valve sleeve 3 can be positioned in a generally cylindrical fashion around the annular element 20a so as to improve the sealing capability of the prosthesis 1 to the valve annulus.
Various modifications and additions can be made to the exemplary embodiments discussed without departing from the scope of the present invention. Accordingly, the scope of the present invention is intended to embrace all such alternatives, modifications, and variations as fall within the scope of the claims, together with all equivalents thereof.
Number | Date | Country | Kind |
---|---|---|---|
TO2005A0074 | Feb 2005 | IT | national |
Number | Name | Date | Kind |
---|---|---|---|
3657744 | Ersek | Apr 1972 | A |
3671979 | Moulopoulos | Jun 1972 | A |
3997923 | Possis | Dec 1976 | A |
4056854 | Boretos et al. | Nov 1977 | A |
4086665 | Poirier | May 1978 | A |
4451936 | Carpentier et al. | Jun 1984 | A |
4477930 | Totten et al. | Oct 1984 | A |
4506394 | Bedard | Mar 1985 | A |
4692164 | Dzemeshkevich et al. | Sep 1987 | A |
4758151 | Arru et al. | Jul 1988 | A |
4777951 | Cribier et al. | Oct 1988 | A |
4994077 | Dobben | Feb 1991 | A |
5084151 | Vallana et al. | Jan 1992 | A |
5123919 | Sauter et al. | Jun 1992 | A |
5133845 | Vallana et al. | Jul 1992 | A |
5139515 | Robicsek | Aug 1992 | A |
5314468 | Martinez et al. | May 1994 | A |
5332402 | Teitelbaum | Jul 1994 | A |
5370685 | Stevens | Dec 1994 | A |
5387247 | Vallana et al. | Feb 1995 | A |
5397351 | Pavcnik et al. | Mar 1995 | A |
5411552 | Andersen et al. | May 1995 | A |
5423886 | Arru et al. | Jun 1995 | A |
5545214 | Stevens | Aug 1996 | A |
5545215 | Duran | Aug 1996 | A |
5554185 | Block et al. | Sep 1996 | A |
5712953 | Langs | Jan 1998 | A |
5716417 | Girard et al. | Feb 1998 | A |
5824037 | Fogarty et al. | Oct 1998 | A |
5824064 | Taheri | Oct 1998 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5855597 | Jayaraman | Jan 1999 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5876436 | Vanney et al. | Mar 1999 | A |
5891195 | Klostermeyer et al. | Apr 1999 | A |
5925063 | Khosravi | Jul 1999 | A |
5954766 | Zadno-Azizi et al. | Sep 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
5980570 | Simpson | Nov 1999 | A |
6162245 | Jayaraman | Dec 2000 | A |
6168614 | Andersen et al. | Jan 2001 | B1 |
6197143 | Bodnar | Mar 2001 | B1 |
6245102 | Jayaraman | Jun 2001 | B1 |
6270526 | Cox | Aug 2001 | B1 |
6299638 | Sauter | Oct 2001 | B1 |
6309417 | Spence et al. | Oct 2001 | B1 |
6312462 | McDermott et al. | Nov 2001 | B1 |
6352554 | De Paulis | Mar 2002 | B2 |
6402780 | Williamson, IV et al. | Jun 2002 | B2 |
6425916 | Garrison et al. | Jul 2002 | B1 |
6440164 | DeMatteo et al. | Aug 2002 | B1 |
6454799 | Schreck | Sep 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6482228 | Norred | Nov 2002 | B1 |
6494909 | Greenhalgh | Dec 2002 | B2 |
6544285 | Thubrikar et al. | Apr 2003 | B1 |
6569196 | Vesely | May 2003 | B1 |
6582462 | Andersen et al. | Jun 2003 | B1 |
6652578 | Bailey et al. | Nov 2003 | B2 |
6656219 | Wiktor | Dec 2003 | B1 |
6685739 | DiMatteo et al. | Feb 2004 | B2 |
6730118 | Spenser et al. | May 2004 | B2 |
6733525 | Yang et al. | May 2004 | B2 |
6790230 | Beyersdorf et al. | Sep 2004 | B2 |
6805711 | Quijano et al. | Oct 2004 | B2 |
6830584 | Seguin | Dec 2004 | B1 |
6830585 | Artof et al. | Dec 2004 | B1 |
6875231 | Anduiza et al. | Apr 2005 | B2 |
6929653 | Strecter | Aug 2005 | B2 |
7018404 | Holmberg et al. | Mar 2006 | B2 |
7125418 | Duran et al. | Oct 2006 | B2 |
7175656 | Khairkhahan | Feb 2007 | B2 |
7186265 | Sharkawy et al. | Mar 2007 | B2 |
7211107 | Bruckheime | May 2007 | B2 |
7252682 | Seguin | Aug 2007 | B2 |
7255706 | Rosengart | Aug 2007 | B2 |
7261732 | Justino | Aug 2007 | B2 |
7276078 | Spenser et al. | Oct 2007 | B2 |
7329278 | Seguin et al. | Feb 2008 | B2 |
7329279 | Haug et al. | Feb 2008 | B2 |
7347869 | Hojeibane et al. | Mar 2008 | B2 |
7351256 | Hojeibane et al. | Apr 2008 | B2 |
7377938 | Sarac et al. | May 2008 | B2 |
7377941 | Rhee et al. | May 2008 | B2 |
7381218 | Schreck | Jun 2008 | B2 |
7393360 | Spenser et al. | Jul 2008 | B2 |
7534259 | Lashinski et al. | May 2009 | B2 |
7556645 | Lashinski et al. | Jul 2009 | B2 |
7569071 | Haverkost et al. | Aug 2009 | B2 |
7578843 | Shu | Aug 2009 | B2 |
7585321 | Cribier | Sep 2009 | B2 |
7591848 | Allen | Sep 2009 | B2 |
7618446 | Andersen et al. | Nov 2009 | B2 |
7618447 | Case et al. | Nov 2009 | B2 |
7708775 | Rowe et al. | May 2010 | B2 |
20010002445 | Vesely | May 2001 | A1 |
20010007956 | Letac et al. | Jul 2001 | A1 |
20010010017 | Letac et al. | Jul 2001 | A1 |
20010039450 | Pavcnik et al. | Nov 2001 | A1 |
20020042651 | Liddicoat et al. | Apr 2002 | A1 |
20020058994 | Hill et al. | May 2002 | A1 |
20020058995 | Stevens | May 2002 | A1 |
20020123802 | Snyders | Sep 2002 | A1 |
20020128702 | Menz et al. | Sep 2002 | A1 |
20020133226 | Marquez et al. | Sep 2002 | A1 |
20020138138 | Yang | Sep 2002 | A1 |
20020151970 | Garrison et al. | Oct 2002 | A1 |
20020198594 | Schreck | Dec 2002 | A1 |
20030014104 | Cribier | Jan 2003 | A1 |
20030023300 | Bailey et al. | Jan 2003 | A1 |
20030023303 | Palmaz et al. | Jan 2003 | A1 |
20030036795 | Andersen et al. | Feb 2003 | A1 |
20030055495 | Pease et al. | Mar 2003 | A1 |
20030109924 | Cribier | Jun 2003 | A1 |
20030130729 | Paniagua et al. | Jul 2003 | A1 |
20030149476 | Damm et al. | Aug 2003 | A1 |
20030153974 | Spenser et al. | Aug 2003 | A1 |
20030163194 | Quijano et al. | Aug 2003 | A1 |
20030191528 | Quijano et al. | Oct 2003 | A1 |
20030208261 | Thorpe et al. | Nov 2003 | A1 |
20040034407 | Sherry | Feb 2004 | A1 |
20040034411 | Quijano et al. | Feb 2004 | A1 |
20040039436 | Spenser et al. | Feb 2004 | A1 |
20040049266 | Anduiza et al. | Mar 2004 | A1 |
20040055606 | Hendricksen et al. | Mar 2004 | A1 |
20040078072 | Tu et al. | Apr 2004 | A1 |
20040078074 | Anderson et al. | Apr 2004 | A1 |
20040093060 | Seguin et al. | May 2004 | A1 |
20040093070 | Hojeibane et al. | May 2004 | A1 |
20040093075 | Kuehne | May 2004 | A1 |
20040106976 | Bailey et al. | Jun 2004 | A1 |
20040260389 | Case et al. | Dec 2004 | A1 |
20050010285 | Lambrecht et al. | Jan 2005 | A1 |
20050033398 | Seguin | Feb 2005 | A1 |
20050075584 | Cali | Apr 2005 | A1 |
20050075712 | Biancucci et al. | Apr 2005 | A1 |
20050075713 | Biancucci et al. | Apr 2005 | A1 |
20050075717 | Nguyen et al. | Apr 2005 | A1 |
20050075718 | Nguyen et al. | Apr 2005 | A1 |
20050075719 | Bergheim | Apr 2005 | A1 |
20050075720 | Nguyen et al. | Apr 2005 | A1 |
20050075724 | Svanidze et al. | Apr 2005 | A1 |
20050075726 | Svanidze et al. | Apr 2005 | A1 |
20050075728 | Nguyen et al. | Apr 2005 | A1 |
20050075729 | Nguyen et al. | Apr 2005 | A1 |
20050075730 | Myers et al. | Apr 2005 | A1 |
20050075731 | Artof et al. | Apr 2005 | A1 |
20050137686 | Salahieh et al. | Jun 2005 | A1 |
20050137687 | Salahieh et al. | Jun 2005 | A1 |
20050137688 | Salahieh et al. | Jun 2005 | A1 |
20050137689 | Salahieh et al. | Jun 2005 | A1 |
20050137690 | Salahieh et al. | Jun 2005 | A1 |
20050137691 | Salahieh et al. | Jun 2005 | A1 |
20050137692 | Haug et al. | Jun 2005 | A1 |
20050137693 | Haug et al. | Jun 2005 | A1 |
20050137694 | Haug et al. | Jun 2005 | A1 |
20050137695 | Salahieh et al. | Jun 2005 | A1 |
20050137696 | Salahieh et al. | Jun 2005 | A1 |
20050137697 | Salahieh et al. | Jun 2005 | A1 |
20050137698 | Salahieh et al. | Jun 2005 | A1 |
20050137699 | Salahieh et al. | Jun 2005 | A1 |
20050137701 | Salahieh et al. | Jun 2005 | A1 |
20050137702 | Haug et al. | Jun 2005 | A1 |
20050143809 | Salahieh et al. | Jun 2005 | A1 |
20050197695 | Stacchino et al. | Sep 2005 | A1 |
20050222675 | Sauter | Oct 2005 | A1 |
20050234546 | Nugent et al. | Oct 2005 | A1 |
20050261759 | Lambrecht et al. | Nov 2005 | A1 |
20060085060 | Campbell | Apr 2006 | A1 |
20060178740 | Stacchino et al. | Aug 2006 | A1 |
20060190017 | Cyr et al. | Aug 2006 | A1 |
20060195184 | Lane et al. | Aug 2006 | A1 |
20060259137 | Artof et al. | Nov 2006 | A1 |
20070032850 | Ruiz et al. | Feb 2007 | A1 |
20070093887 | Case et al. | Apr 2007 | A1 |
20070093890 | Eliasen et al. | Apr 2007 | A1 |
20070100432 | Case et al. | May 2007 | A1 |
20070100435 | Case et al. | May 2007 | A1 |
20070100440 | Figulla et al. | May 2007 | A1 |
20070106372 | Osborne et al. | May 2007 | A1 |
20070118209 | Strecker | May 2007 | A1 |
20070118215 | Moaddeb | May 2007 | A1 |
20070168024 | Khairkhahan | Jul 2007 | A1 |
20070185513 | Woolfson et al. | Aug 2007 | A1 |
20070233228 | Eberhardt et al. | Oct 2007 | A1 |
20070237802 | McKay et al. | Oct 2007 | A1 |
20070239265 | Birdsall et al. | Oct 2007 | A1 |
20070239273 | Allen | Oct 2007 | A1 |
20070244544 | Birdsall et al. | Oct 2007 | A1 |
20070260305 | Drews et al. | Nov 2007 | A1 |
20070265701 | Gurskis et al. | Nov 2007 | A1 |
20070270944 | Bergheim et al. | Nov 2007 | A1 |
20070293942 | Mirzaee | Dec 2007 | A1 |
20080065204 | Macoviak et al. | Mar 2008 | A1 |
20080071369 | Tuval et al. | Mar 2008 | A1 |
20080082164 | Friedman | Apr 2008 | A1 |
20080097595 | Gabbay | Apr 2008 | A1 |
20080125859 | Salahieh et al. | May 2008 | A1 |
20080133033 | Wolff et al. | Jun 2008 | A1 |
20080188880 | Fischer et al. | Aug 2008 | A1 |
20080228263 | Ryan | Sep 2008 | A1 |
20090157175 | Benichou et al. | Jun 2009 | A1 |
20090164006 | Seguin et al. | Jun 2009 | A1 |
20090171456 | Kveen et al. | Jul 2009 | A1 |
20090209955 | Forster et al. | Aug 2009 | A1 |
20090210052 | Forster et al. | Aug 2009 | A1 |
20090222082 | Lock et al. | Sep 2009 | A1 |
20090222084 | Friedman | Sep 2009 | A1 |
20090254165 | Tabor et al. | Oct 2009 | A1 |
Number | Date | Country |
---|---|---|
195 46 692 | Jun 1997 | DE |
198 57 887 | Jul 2000 | DE |
0 133 420 | Feb 1988 | EP |
0 155 245 | May 1990 | EP |
0 592 410 | Oct 1995 | EP |
0 850 607 | Jul 1998 | EP |
1 057 460 | Dec 2000 | EP |
1 088 529 | Apr 2001 | EP |
1 259 194 | Feb 2005 | EP |
1 214 020 | Mar 2005 | EP |
2 055 266 | May 2005 | EP |
1 570 809 | Sep 2005 | EP |
1 014 896 | Nov 2005 | EP |
1 603 493 | Dec 2005 | EP |
1 600 127 | Nov 2006 | EP |
1 143 882 | May 2007 | EP |
1 330 213 | Mar 2009 | EP |
1 370 201 | Sep 2009 | EP |
2 133 039 | Dec 2009 | EP |
1 017 275 | Aug 2002 | NL |
WO 9724989 | Jul 1997 | WO |
WO 9817202 | Apr 1998 | WO |
WO 9829057 | Jul 1998 | WO |
WO 9913802 | Mar 1999 | WO |
WO 9956665 | Nov 1999 | WO |
WO 0041852 | Jul 2000 | WO |
WO 0047139 | Aug 2000 | WO |
WO 0062714 | Oct 2000 | WO |
WO 0062716 | Oct 2000 | WO |
WO 0121107 | Mar 2001 | WO |
WO 0162189 | Aug 2001 | WO |
WO 0164137 | Sep 2001 | WO |
WO 0176510 | Oct 2001 | WO |
WO 0241789 | May 2002 | WO |
WO 02047575 | Aug 2002 | WO |
WO 02078348 | Oct 2002 | WO |
WO 03003943 | Jan 2003 | WO |
WO 03003949 | Jan 2003 | WO |
WO 03094797 | Nov 2003 | WO |
WO 2004082527 | Sep 2004 | WO |
WO 2004091455 | Oct 2004 | WO |
WO 2005046528 | May 2005 | WO |
WO 2006044679 | Apr 2006 | WO |
WO 2006086135 | Aug 2006 | WO |
WO 2009029199 | Mar 2009 | WO |
Number | Date | Country | |
---|---|---|---|
20060178740 A1 | Aug 2006 | US |